Empirical antifungal therapy is frequently used in allogeneic transplant patients who have persistent febrile neutropenia and can be associated with high cost, toxicity and breakthrough infections. There are limited reports of strategies for early diagnosis of invasive fungal infection (IFI) and, to our knowledge, no reports of treatment strategies based only on high-resolution computerized tomography (HRCT) scans. We used an early treatment strategy for IFI in 99 consecutive patients undergoing allogeneic transplantation. Patients received caspofungin if they had antibiotic-resistant neutropenic fever for more than 72 h and a positive HRCT scan. Fifty-three of 99 patients (54%) had antibiotic-resistant neutropenic fever at 72 h and would have received parenteral antifungal treatment if an empirical approach had been used. The HRCT-based strategy reduced the use of parenteral antifungal agents to 17/99 patients (17%), a 68% reduction. No subsequent diagnoses of IFI occurred within 100 days in patients with a negative HRCT. Only one patient died from IFI within 100 days. These data suggest that this non-empirical strategy may be feasible and that caspofungin may be effective in this setting. A randomized controlled trial is warranted to further assess these results.
Introduction
Invasive fungal infections (IFIs) remain a significant cause of morbidity and mortality in patients undergoing allo-SCT. It has been standard practice in many centres to initiate empirical therapy for fungal infections in patients who have persistent neutropenic fever. This approach has been incorporated into several guidelines.
1,2 Approximately 40-50% of patients may be treated with antifungals using this empirical approach, whereas the estimated actual incidence of IFI is around 10-15%. 3 As a result, many patients are potentially exposed to unnecessary treatment with associated potential toxicity and considerable financial burden. Recent guidelines suggest that empirical treatment should be discouraged. 4, 5 Early diagnosis of IFI can be challenging. Invasive tests such as bronchoscopy and lung biopsy can be difficult to perform in hypoxic patients. Non-culture-based microbiological techniques such as galactomannan may have a role, but these tests can have a lower sensitivity in patients receiving mould-active azoles as prophylaxis and falsepositive results can occur with piperacillin-tazobactam antibiotics, which are used in many units. 6, 7 Standard chest radiography can show nonspecific or normal results. 8, 9 Computerized tomography, in particular, high-resolution computerized tomography (HRCT), has been shown to demonstrate early predictive signs of fungal infection, including the halo sign. [10] [11] [12] [13] Major signs on CT scans have also been shown to precede serum galactomannan testing. 14 To date, there are little data on strategies for early diagnosis of fungal infection. Maertens et al. 15 report a preemptive treatment strategy based on HRCT, bronchoscopy with lavage and seropositive galactomannan results. Only seropositive patients, and those with a positive microbiological test result and supportive radiological findings received liposomal amphotericin B. They reported a 78% reduction in antifungal use with this strategy in patients undergoing chemotherapy for acute leukaemia or myeloablative SCT. It is important to note that extended spectrum azoles were not used as prophylaxis in this study. In another European study among neutropenic patients with haematological malignancy, pre-emptive treatment based on clinical features, galactomannan and microbiological criteria were compared with empirical treatment. 16 There was less antifungal usage in the pre-emptive arm, but more fungal infections were observed. A German study compared empirical therapy with pre-emptive treatment based on fungal genomic detection by PCR analysis of serial serum samples. More patients received treatment in the pre-emptive arm, and although the 30-day mortality rate was reduced, the 100-and 180-day mortality rates remained unchanged. 17 Oshima et al. 18 report the feasibility of a presumptive treatment strategy based on positive serum test and/or infiltrates or nodules on X-ray or CT scan associated with persistent febrile neutropenia after allogeneic transplantation. Patients received a variety of antiAspergillus agents.
In January 2006, the antifungal guidelines at the Royal Marsden Hospital were changed to include a strategy for early investigation and treatment of potential IFI in patients after allogeneic transplantation. The aim of the study was to assess the feasibility of an early treatment strategy based on high-resolution CT scan results and to avoid the use of empirical antifungal therapy. Caspofungin was used as first-line treatment in view of its excellent safety profile and lack of interactions with other antibacterial agents. 19 Caspofungin was chosen over voriconazole as a first-line agent because all patients received extended spectrum azoles as prophylaxis and there was concern that breakthrough infections may be resistant to azole treatment. Serum testing was not used in view of the risk of false-positive results with piperacillin-tazobactam, which was used as a first-line antibacterial agent, and low sensitivity in patients receiving extended spectrum azoles, which were used as prophylaxis against IFI. Bronchoalveolar lavage was conducted at the discretion of the treating physician.
Design and methods

Patient population
The Royal Marsden computer database was used to identify all adult patients who had received an allo-SCT from 1 January 2006 to 31 December 2007. Informed consent was undertaken at the time of consenting patients to BMT. The study protocol was approved by the Royal Marsden Hospital audit committee. Data were collected retrospectively by reviewing the electronic patient record, patient notes and drug charts. All consecutive patients who received an allogeneic transplant in 2006 and 2007 were included in the study. Patients who had received an allogeneic transplant before 2006 were excluded, as the early treatment strategy was not incorporated into the antifungal guidelines at the Royal Marsden Hospital at that time.
Study procedures
All patients were hospitalized in single rooms with HEPA filters from the start of therapy until neutrophil recovery (ANC, X0.5 Â 10 9 cells/l). Antifungal prophylaxis consisted of itraconazole (200 mg i.v. twice daily loading dose for 2 days and 2.5 mg/kg of oral solution continuing twice daily thereafter). Patients who had an earlier history of suspected fungal infection received oral voriconazole 200 mg twice daily. Gut decontamination was administered by neomycin 500 mg twice daily orally and colistin 1.5 megaunits three times daily, but no routine systemic antibacterial agents were used. Patients were monitored at least every 4 h for development of fever (438 1C) and daily for signs and symptoms of IFI. Blood cultures were taken at the time of first fever and every 48 h that fever persisted. Chest radiographs and urine cultures were performed routinely in febrile patients along with stool and sputum cultures as indicated. Neutropenic fever was treated with gentamicin and piperacillin-tazobactam as first-line agents, and teicoplanin was added if patients had clinically infected central venous catheter sites or a gram-positive organism was grown from blood cultures.
Diagnosis of IFI
Patients were investigated for IFI if they were neutropenic and had antibiotic-resistant fever at 72 h. Patients underwent HRCT of the thorax within 24 h of ongoing fever. HRCT included imaging of 1.25-mm sections at intervals of 10 mm. If HRCT could not be undertaken during this time frame, for example weekends/holidays, caspofungin was commenced until a negative HRCT report was issued. If HRCT showed changes suspicious of fungal infection, caspofungin was commenced. Cavitation, air-crescent sign and halo sign were classified as the major changes. Nodules and new infiltrates, including consolidation and effusions, were classified as minor changes. 13 Caspofungin was also commenced at the discretion of the treating physician if a patient developed respiratory failure requiring high dependency or intensive care regardless of CT findings. A repeat CT scan was undertaken after 10-14 days. If appearances were improving and engraftment had occurred, patients were switched to oral voriconazole. If appearances were worsening or the patient's physician was concerned about clinical deterioration, second-line antifungal agents were commenced. This diagnostic and treatment algorithm is shown in Figure 1 . Broncho-alveolar lavage and biopsies for histological diagnosis were undertaken at the discretion of the treating physician and did not form part of the diagnostic algorithm.
Antifungal treatment
Patients received caspofungin at an initial once only dose of 70 mg i.v., followed by 50 mg i.v. once daily (70 mg 
Results
A total of 99 consecutive patients were investigated.
Patients' characteristics are shown in Table 1 . Eighty-nine patients (90%) developed a fever in the neutropenic period and 53/99 patients (54%) still had a fever at 72 h. Seventeen of the 53 patients (32%) had a positive blood culture result but remained febrile despite appropriate antimicrobial treatment. All 53 patients would have received antifungal treatment if a standard empirical approach based on persistent neutropenic fever had been used. HRCT scans were conducted and reported within 72-96 h of onset of fever in 48/53 patients (91%). Three patients received treatment with caspofungin for one day until the HRCT result was available. These patients were excluded from the antifungal treatment group. Using the CT-based treatment strategy, 36 of these 53 patients (68%) did not receive parenteral antifungal treatment. Twentynine patients had a negative CT scan and seven patients were not commenced on parenteral antifungal agents as the temperature settled before the HRCT was undertaken. This group included those patients who initially defervesced and then developed a further fever.
Caspofungin was commenced in 17/53 patients (32%) with persistent neutropenic fever. Fifteen patients had a positive HRCT scan. Four patients had a halo sign, seven had nodules, one had a pleural effusion and three had consolidation. The patient with a pleural effusion and two of the patients with consolidation also required high dependency or intensive care for respiratory symptoms. A further two patients received caspofungin for 3 days until HRCT was conducted and reported as negative for fungal infection. Three of 15 patients (20%) with an earlier IFI received caspofungin treatment during the neutropenic period.
In total, 17/99patients (17%) received parenteral antifungal treatment in the early neutropenic period compared with 53/99 patients (54%) who would have received antifungal treatment had an empirical strategy been used. The non-empirical strategy reduced the use of parenteral antifungal agents by 68%.
Patients' outcome Seventeen patients received caspofungin as first-line antifungal treatment. Four patients were engrafted (ANC 40.5 Â 10 9 cells/l for 3 days) at the time of commencing caspofungin after a period of neutropenic fever. The response to treatment was assessed by improvement of HRCT and clinical condition. Eleven patients responded and only one died within 100 days of starting caspofungin. This patient died of respiratory infection with CMV. The three patients with a history of IFI responded to treatment. The remaining six patients went on to receive second-line antifungal drugs. Two patients in this group died within 100 days of starting caspofungin, although in only one patient the primary cause of death was fungal infection. This patient had a broncho-alveolar lavage, which was positive for Aspergillus fumigatus and died from respiratory infection.
Thirty-six patients did not receive antifungal agents despite persistent fever at 72 h. Three patients in this group went on to receive antifungal agents within 100 days of persistent fever. Two of these patients received empirical treatment, as they required invasive ventilation. Both of these patients recovered. The third patient died of enterococcal septicaemia. None of this group had probable or proven IFI. An overview of patients' outcome is shown in Figure 2 . One patient was excluded from the analysis of the early treatment strategy on account of receiving liposomal amphotericin B and voriconazole at the time of transplantation, and died of relapsed disease on day þ 2 following transplant.
Long-term follow-up
The 99 patients who underwent allogeneic transplantation were followed up for a median of 13 months (range 3-27 months). In addition to the 17 patients who received caspofungin first line during the neutropenic period, 17 patients were treated after engraftment. The median duration of treatment was 13 days (range 3-45 days). The median time of commencing treatment was day þ 20 (À1 to þ 520). In total, 20/34 patients (59%) responded to treatment. Thirteen of these patients were alive at the time of the last follow-up and seven have died. Fourteen patients (41%) did not respond to caspofungin and required a second-line agent. Three patients are alive and 11 have died. In two of these patients, fungal infection was felt to be the primary cause of death. In addition to the probable case of Aspergillus sp documented above, a further patient had broncho-alveolar lavage that was positive for Aspergillus fumigatus and Candida glabrata. The causes of mortality are detailed in Table 2 . A further eight patients received an alternative first-line antifungal agent. Five of these patients received liposomal amphotericin B, and further patients received liposomal amphotericin B and voriconazole. This group included two patients with proven infection according to the European Organization for Research and Treatment of Cancer criteria. 20 . One patient had a histological diagnosis of Mucor infection and another grew Candida glabrata in blood cultures. The others received liposomal amphotericin B at the discretion of the treating physician. One patient received posaconazole and one received oral voriconazole as they were receiving essentially palliative treatment as outpatients. In the group treated with an alternative antifungal agent, one patient died of IFI.
Overall, 42/99 patients (42%) received parenteral antifungal treatment in the entire post transplant follow-up period. The incidence of probable and proven fungal infection during the study period was 4/99 patients (4%). Three of 99 patients (3%) died of IFI. The causes of death in this patient group were not confirmed by autopsy as post-mortem examination was frequently declined by relatives. However, the clinical, microbiological and histological data for each patient who died were reviewed in detail. Bronchoscopy results were available for 6/11 patients (55%) who died of respiratory failure. It was not conducted in the remaining patients in view of severe hypoxia and concerns that the procedure would precipitate intubation. IFI was considered to be the primary cause of death if there was one positive microbiological result on broncho-alveolar lavage regardless of any other organisms present. Responded (11) Alive (10) 1 Death: resp, other organism Received antifungals within 100 days
Did not receive antifungals (33) 
Discussion
Empirical antifungal treatment is used in many centres for high-risk patients with persistent neutropenic fever. There are only a few reports to date of effective diagnostic strategies that would permit early treatment of IFI while avoiding unnecessary toxicity. [15] [16] [17] [18] These studies have been based on the use of positive serum tests, broncho-alveolar lavage and radiological findings. To the best of our knowledge, this report is the first to investigate an early treatment strategy based only on high-resolution CT scanning. This strategy is easier to implement in clinical practice as HRCT is a non-invasive investigation that avoids the potential difficulties of false results with serum testing. 6 This report is also among the first to report the outcome of using first-line treatment with caspofungin in this group of patients.
Radiological investigations, including chest radiograph, conventional CT scans and high-resolution CT scans, have been used frequently in the diagnosis of IFI. Early signs include the halo sign, whereas later signs include the aircrescent sign and cavitation. [8] [9] [10] [11] [12] [13] Often, by the time these signs develop, the patient is seriously unwell. This report uses high-resolution CT scanning to try and identify the early IFI by looking for nodules, as well as for the classical signs of fungal infection. These data show that this is a safe strategy, as patients with persistent neutropenic fever but a negative HRCT scan did not have a subsequent diagnosis or death from IFI within 100 days. One limitation of this study is that findings on HRCT can be nonspecific and patients may still have received antifungal therapy unnecessarily. Despite this problem, only 17/99 patients (17%) received parenteral antifungal treatment during the early neutropenic period compared with 53/99 patients (54%) who would have received antifungal treatment had an empirical strategy been used. These results represent a 68% reduction in antifungal usage.
There are several other limitations of this study. The data were collected retrospectively and may therefore be limited in terms of the accuracy of data collection. This risk is significantly reduced, however, by the use of the electronic patient record, thereby avoiding problems connected with missing notes or drug charts. In addition, by not using serum testing, it is possible that fungal infections may have been missed in the group not treated with antifungal agents. This seems unlikely, however, as 34 of these 36 patients (94%) were alive at 100 days of follow-up. The use of piperacillin-tazobactam and extended spectrum azoles in this group may also have affected the performance of serum testing. Finally, this study reports the results of two non-standard interventions: the use of HRCT and the use of first-line caspofungin. Prospective studies would be helpful to review the relative effect of each intervention.
Caspofungin was used in this study because of the excellent safety profile of this drug. There have been limited reports to date of the use of caspofungin as a first-line agent in the setting of allogeneic transplantation. One report detailed an increased number of breakthrough infections, but caspofungin was being used empirically in this centre. 21 Encouraging results have been reported in patients receiving chemotherapy or undergoing solid organ transplantation. [22] [23] [24] [25] It has proven efficacy as second-line therapy for invasive aspergillosis 26 and has also been used in combination with other agents. 27 These data are supported by the current study, which suggests that caspofungin may be an effective first-line antifungal agent in the setting of allogeneic transplantation. In total, of 34 patients who received caspofungin as first-line treatment, 20 patients responded to treatment. No patient had to stop using caspofungin in view of toxicity.
In conclusion, a CT-based treatment strategy for IFI in allogeneic transplant patients was used for a two-year time period. This strategy seemed to be feasible and may help to reduce toxicity, cost and breakthrough infections associated with antifungal usage. Caspofungin may be an effective first-line treatment in this setting. A randomized controlled trial would be useful to assess both this diagnostic strategy and the role of caspofungin.
